(Q24247745)

https://api.crossref.org/works/10.1002%2F14651858.CD003574.PUB2

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003574.PUB2

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003574.PUB2

Infliximab for the treatment of fistulas in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003574.PUB2

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003574.PUB2

Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003574.PUB2

Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003574.PUB2

Review article: the clinical role of anti-TNFalpha antibody treatment in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003574.PUB2

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003574.PUB2

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003574.PUB2

Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003574.PUB2

Tumor necrosis factor: biology and therapeutic inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003574.PUB2

Accuracy of data in abstracts of published research articles

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003574.PUB2

Management of Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003574.PUB2

Increased production of tumour necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003574.PUB2

Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003574.PUB2

Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003574.PUB2

Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003574.PUB2

7 January 2021

The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003574.PUB2

7 January 2021

Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003574.PUB2

7 January 2021

Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003574.PUB2

7 January 2021

Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003574.PUB2

7 January 2021

Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003574.PUB2

7 January 2021

An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003574.PUB2

7 January 2021

Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003574.PUB2

7 January 2021

10.1002/14651858.CD003574.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

14974022

1 reference

Consolidated OpenCitations Corpus – April 2017